Literature DB >> 9336336

Kinetic evidence for active efflux transport across the blood-brain barrier of quinolone antibiotics.

T Ooie1, T Terasaki, H Suzuki, Y Sugiyama.   

Abstract

A distributed model has been used to clarify the mechanism of the restricted and differential distribution of the quinolone antibiotics in the rat central nervous system (CNS). The symmetrical permeability clearances across the blood-brain barrier (BBB), PS(BBB), and across the blood-cerebrospinal fluid barrier (BCSFB), PS(CSF), and the active efflux clearances across the BBB, PS(BBB,eff), were obtained from a nonlinear least squares regression analysis combined with the fast inverse Laplace transforming program for in vivo data. The values of PS(BBB,eff) were 10- to 260-fold greater than those of PS(BBB), providing kinetic evidence to support the hypothesis that a significant efflux transport across the BBB is responsible for the limited distribution of quinolones in brain tissue. Moreover, by simulation studies, we could demonstrate the concentration profiles in the brain as a function of the distance from the ependymal surface. However, active efflux transport across the BCSFB has been suggested to have only a slight effect on the apparent elimination from the cerebrospinal fluid. Comparing the apparent brain tissue-to-unbound serum concentration ratio at steady state, it has been suggested that the net flux across the BBB, ie., the ratio of PS(BBB) to the sum of PS(BBB) and PS(BBB,eff), is a determinant for the differential distribution of these quinolones in brain tissue. Such a putative active efflux transport system would play a significant role in decreasing the brain interstitial fluid concentration of quinolones.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9336336

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  14 in total

Review 1.  The impact of efflux transporters in the brain on the development of drugs for CNS disorders.

Authors:  Eve M Taylor
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 2.  Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain.

Authors:  Elizabeth C M de Lange; Meindert Danhof
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 3.  How to measure drug transport across the blood-brain barrier.

Authors:  Ulrich Bickel
Journal:  NeuroRx       Date:  2005-01

Review 4.  Physiologically based pharmacokinetic modelling of drug penetration across the blood-brain barrier--towards a mechanistic IVIVE-based approach.

Authors:  Kathryn Ball; François Bouzom; Jean-Michel Scherrmann; Bernard Walther; Xavier Declèves
Journal:  AAPS J       Date:  2013-06-20       Impact factor: 4.009

Review 5.  Prodrug approaches for CNS delivery.

Authors:  Jarkko Rautio; Krista Laine; Mikko Gynther; Jouko Savolainen
Journal:  AAPS J       Date:  2008-02-05       Impact factor: 4.009

Review 6.  Microdialysis: the Key to Physiologically Based Model Prediction of Human CNS Target Site Concentrations.

Authors:  Yumi Yamamoto; Meindert Danhof; Elizabeth C M de Lange
Journal:  AAPS J       Date:  2017-03-09       Impact factor: 4.009

7.  Pharmacokinetic-pharmacodynamic contributions to the convulsant activity of fluoroquinolones in rats.

Authors:  A Delon; S Bouquet; F Huguet; V Brunet; P Courtois; W Couet
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

Review 8.  Toward the prediction of CNS drug-effect profiles in physiological and pathological conditions using microdialysis and mechanism-based pharmacokinetic-pharmacodynamic modeling.

Authors:  Elizabeth C M de Lange; Paulien G M Ravenstijn; Dorien Groenendaal; Tamara J van Steeg
Journal:  AAPS J       Date:  2005-10-07       Impact factor: 4.009

Review 9.  Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development.

Authors:  Sumio Ohtsuki; Tetsuya Terasaki
Journal:  Pharm Res       Date:  2007-07-10       Impact factor: 4.200

Review 10.  On the rate and extent of drug delivery to the brain.

Authors:  Margareta Hammarlund-Udenaes; Markus Fridén; Stina Syvänen; Anubha Gupta
Journal:  Pharm Res       Date:  2007-12-05       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.